$SNEX

Dunaway William J sold $8.3M of SNEX

Dunaway William J (Chief Financial Officer) sold 63,602 shares of StoneX Group Inc. (SNEX) at $131.16 ($8.34M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dunaway William J
Published Jun 15, 2026, 11:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
medium confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

The CFO’s open-market sale (63,602 shares) is newly disclosed and could slightly influence sentiment, but the presence of a pre-arranged 10b5-1 plan lowers the probability it signals new negative information.

02

Market read

A fresh insider-sale datapoint for SNEX, likely to have only marginal trading impact absent additional fundamental news.

03

What to watch

Traders may overreact to insider sales; the key is whether there are concurrent buys/sales by other insiders or any new company disclosures beyond this Form 4.

Relevance 5/10Novelty 6/10Timing: Filed June 15; sale executed June 12 under a 10b5-1 plan

Background

The article is an SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralMedium confidence
Context

StoneX CFO William J. Dunaway sold 63,602 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any reaction should be small unless accompanied by other new fundamentals.

Evidence & confidence

Form 4 provides a fresh, company-specific ownership-change datapoint, but 10b5-1 pre-arrangement typically indicates planned diversification rather than new information.

Market effects

Minimal; this is a single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/diversification rather than bearish expectations.

Key entities

  • StoneX Group Inc.

    Company whose CFO filed the Form 4 insider sale disclosure.

  • William J. Dunaway

    Chief Financial Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.